SEC Company Response from ZEVRA THERAPEUTICS, INC. (ZVRA) (CIK 0001434647) (ZVRA) — Apr 3, 2015
ZEVRA THERAPEUTICS, INC. (ZVRA) (CIK 0001434647)
Date: April 3, 2015 · CIK: 0001434647 · Accession: 0001193125-15-119083
AI Filing Summary & Sentiment
File numbers found in text: 333-202660
Referenced dates: March 31, 2015
Show Raw Text
CORRESP
1
filename1.htm
CORRESP
Brent B. Siler
T:
+1 202 728 7040
bsiler@cooley.com
VIA EDGAR
April 3, 2015
United States Securities and
Exchange Commission
100 F Street, N.E.
Mail
Stop 4720
Washington, D.C. 20549
Attn:
Mr. Jeffrey Riedler
Ms. Keira Nakada
Mr. Jim Rosenberg
Mr. Preston Brewer
Mr. Daniel Greenspan
Re:
KemPharm, Inc.
Registration Statement on Form S-1
Filed March 11, 2015
File No. 333-202660
Ladies and Gentlemen:
On behalf of our client, KemPharm, Inc. (the “Company”), we are responding to the comment of the staff (the
“Staff”) of the Securities and Exchange Commission (the “Commission”) contained in its letter dated March 31, 2015 (the “Comment Letter”) relating to the Company’s
above referenced Registration Statement on Form S-1 filed on March 11, 2015 (the “Registration Statement”), as amended by Amendment No. 1 to the Registration Statement filed on April 3, 2015 (the
“Amendment”). For the Staff’s reference, we are also delivering both a clean copy of the Amendment and a copy marked to show all changes from the Registration Statement filed on March 11, 2015.
Set forth below are the Company’s responses to the Staff’s comments set forth in the Comment Letter. The numbering of the paragraph below
corresponds to the numbering of the comment, which for your convenience we have incorporated into this response letter.
Non-Management
Directors, page 126
1.
Please expand the discussion concerning Mr. Tierney to provide a discussion of his employment, if any, during 2012.
ONE FREEDOM SQUARE, RESTON TOWN CENTER, 11951 FREEDOM DRIVE, RESTON, VA 20190-5656 T: (703)
456-8000 F: (703) 456-8100 WWW.COOLEY.COM
April 3, 2015
Page Two
Response to Comment 1:
The Company respectfully advises the Staff that Dr. Tierney was not employed during 2012. Accordingly, as discussed with the Staff, the
Company has not expanded its discussion concerning Dr. Tierney in the Amendment.
* * *
The Company acknowledges that:
•
should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
•
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the
disclosure in the filing; and
•
the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
* * *
Please fax any additional comment letters concerning the Amendment to (202) 842-7899 and direct any questions or comments concerning this response
letter to either the undersigned at (202) 728-7040 or Matthew P. Dubofsky, of Cooley LLP’s Colorado office, at (720) 566-4244.
Sincerely,
Cooley LLP
/s/ Brent B.
Siler
Brent B. Siler
cc:
Gordon K. Johnson, KemPharm, Inc.
James C. T. Linfield, Cooley LLP
Matthew P. Dubofsky, Cooley LLP
David W. Pollak, Morgan, Lewis & Bockius LLP
ONE FREEDOM SQUARE, RESTON TOWN CENTER, 11951 FREEDOM DRIVE, RESTON, VA 20190-5656 T: (703)
456-8000 F: (703) 456-8100 WWW.COOLEY.COM